Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q3 2025 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, Nov 6, 2025
Slide 1: Q3 2025 Continued Growth Momentum and Strengthened Profitability
November 6th, 2025 Q3 2025 CEO Michael Akoh CFO Børge Sørvoll CCO Paul Blackburn Continued Growth momentum and Strengthened Profitability
Slide 2: Overview
Overview Overview ADriving Norwegian biotechProfitable Sustainable, with growth Growth potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced therapies and molecular considerable growth Segment & Customers science to
Slide 3: Agenda
Agenda 1 Highlights Q3 and Strategy Overview 2 Sales – Biomanufacturing & Molecular Tools 3 Financials 4 Outlook and Q&A
Slide 4: Highlights Q3 2025: Profitable Growth Across Core Segments
Highlights Q3 2025: Profitable Growth Across Core Segments Total Brenntag Molecular tools revenue up 24% European back on a growth 29.8 MNOK partnership deal path (24.1 MNOK) executed +45% YoY EBITDA GMP Nuclease up growth Biomanufacturing 3.5 MNOK 26% of 23% growth YTD (-2.3 MNOK) Biomanufacturing
Slide 5: Strategic Overview
Strategic Overview Strategic Direction and Core Pillars AZT 2026 – Scaling Through Customer Centricity Transformation • Transition from a product-oriented enzyme supplier to a customer-driven solutions partner • Scale to meet global demand, strengthen customer intimacy, and evaluate inorganic growth
Slide 6: Sales Update Q3 2025
Sales Update Q3 2025
Slide 7: Exclusive Partnership
Exclusive Partnership ArcticZymes’ enzyme innovation meets Brenntag’s commercial scale What? Why? Impact? Exclusive distribution Strategic alignment: Improved customer partnership Combines Brenntag Pharma’s access for Salt Active Nuclease (SAN) life-science focus with Greater sales touchpoints and a
Slide 8: Q3 Sales - Overview
Q3 Sales - Overview Biomanufacturing and Molecular Tools Total sales up in Q3-2025 vs Q3-2024 (28.5MNOK vs Combined Sales 23.3 MNOK, +24%) Sales in Biomanufacturing reasonable following an 35 exceptionally strong Q2-2025. 30 Sales in Molecular Tools also strong, even excluding our one significant cu
Slide 9: Q3 Sales - Biomanufacturing
Q3 Sales - Biomanufacturing Steady Performance with Expanding Customer Base Rebalancing of sales growth vs previous quarter of Biomanufacturing sales 13.0 MNOK 20 GMP versions continue to show steady growth, with sales of 3.36 MNOK (vs 1.23 MNOK Q2) 15 Increase in ELISA kit sales with significant co
Slide 10: Strong leading indicator of future growth
Strong leading indicator of future growth Unique customers and Order Trends Unique Bioprocess Customers Lower Biomanufacturing AOV due to increased number of 120 smaller validation projects 110 106 103 Leading indicator for R&D testing projects – underpinning 100 future growth 87 80 75 58 60 43 40 2
Slide 11: Q3 Sales - Molecular Tools
Q3 Sales - Molecular Tools Underlying business intact Strong growth in diverse customer mix showing Molecular Tool Sales focus on key applications 25 Large customer returned to standard purchasing patterns Good performance of core molecular tools 20 business 15 Sales in MNOK 10 5 45% growth in Molec
Slide 12: Q1-Q3 YTD Revenue Summary
Q1-Q3 YTD Revenue Summary Annual Revenue Overview Total Revenues –1.9% (+22%) US +16% ; EMEA –21.3% (26%) ; APAC 52% Biomanufacturing +22% US 10%; EMEA 49%; APAC 20% Molecular Tools –21% US +32%; EMEA – 43% (-9%): APAC +276% 12
Slide 13: Expenses & Profitability
® OF Expenses & Profitability ae “X% ge ~e
Slide 14: Profit and loss, Expense development
Profit and loss, Expense development Continued cost control Personnel expenses Q3 YTD 2025 2024 2025 2024 Increased investment in commercial Sales revenues 28,5 23,3 78,5 79,8 team Other revenues 1,2 0,8 5,0 1,9 Sum revenues 29,8 24,1 83,6 81,7 Reduced capitalisation Cost of materials -0,6 -4,7 -2,7
Slide 15: Currency impact
USDNOK Currency impact 12 11,5 Slightly negative for the quarter 11 10,5 Majority of revenues are in foreign currency 10 70% in USD 9,5 9 30% in EURO 8,5 73% in USD and 27% in EURO for 2024 2024 2025 EURNOK Currency effect on P&L 12,2 Finance 12 Decrease of 0.4 MNOK in Q3 (0.0 MNOK in Q3 11,8 2024)
Slide 16: Profitability and expenses
Profitability and expenses Another good quarter Q3 YTD Sales 35 2025 2024 2025 2024 EBITDA Sales revenues 28,5 23,3 78,5 79,8 30 Other revenues 1,2 0,8 5,0 1,9 Sum revenues 29,8 24,1 83,6 81,7 25 Cost of materials -0,6 -4,7 -2,7 -7,2 20 Change in inventory -0,1 3,7 -0,4 2,8 Personnel expenses -18,9
Slide 17: Cash flow and short-term investments
Cash flow and short-term investments 11.5 MNOK in changes for Q3* Cash and STI position 280 30 Short term investments (STI) Net Cash (MNOK) 25 260 Changes in Cash and STI (MNOK) 20 240 Changes in cash and STI (MNOK) 15 Net Cash (MNOK) 220 10 200 5 180 0 160 -5 140 -10 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Slide 18: Outlook 2025
Outlook 2025 Biomanufacturing • Brenntag partnership is expected to be a long-term growth driver • CDMO partnership accelerating, 192% growth YTD Molecular Tools • Major partner back on track - >10% growth from other key accounts in Q3, signaling renewed momentum • M-SAN adoption expanding, now inte
Slide 19: Thank you Q & A
ArcticZymes Technologies *
ArcticZymes Technologies — Q3 2025 Earnings Presentation on 6ix